These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M. Clin J Am Soc Nephrol; 2008 Jul; 3(4):1006-14. PubMed ID: 18417741 [Abstract] [Full Text] [Related]
10. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Clin J Am Soc Nephrol; 2008 Jul 01; 3(4):1077-83. PubMed ID: 18417744 [Abstract] [Full Text] [Related]
11. Epoetin alfa in the critically ill: What dose? Which route? Napolitano LM. Crit Care Med; 2009 Apr 01; 37(4):1501-3. PubMed ID: 19318838 [No Abstract] [Full Text] [Related]
12. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M, Epoetin Alfa Extended Dosing Study Group. Clin J Am Soc Nephrol; 2008 Jul 01; 3(4):1015-21. PubMed ID: 18400964 [Abstract] [Full Text] [Related]
13. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Nephrol Dial Transplant; 2007 Mar 01; 22(3):794-800. PubMed ID: 17210593 [Abstract] [Full Text] [Related]